KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Assets: 2009-2025

Historic Assets for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Sep 2025 value amounting to $11.4 billion.

  • Jazz Pharmaceuticals' Assets fell 7.34% to $11.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 billion, marking a year-over-year decrease of 7.34%. This contributed to the annual value of $12.0 billion for FY2024, which is 5.43% up from last year.
  • As of Q3 2025, Jazz Pharmaceuticals' Assets stood at $11.4 billion, which was up 3.77% from $10.9 billion recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Assets registered a high of $13.2 billion during Q2 2021, and its lowest value of $6.8 billion during Q1 2021.
  • Its 3-year average for Assets is $11.4 billion, with a median of $11.4 billion in 2025.
  • Its Assets has fluctuated over the past 5 years, first soared by 117.80% in 2021, then fell by 16.78% in 2022.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Assets stood at $12.3 billion in 2021, then dropped by 11.90% to $10.8 billion in 2022, then increased by 5.15% to $11.4 billion in 2023, then grew by 5.43% to $12.0 billion in 2024, then declined by 7.34% to $11.4 billion in 2025.
  • Its Assets stands at $11.4 billion for Q3 2025, versus $10.9 billion for Q2 2025 and $11.5 billion for Q1 2025.